Overcoming drug resistance in skin cancer
Cancer types:
Skin cancer
Project period:
–
Research institute:
Massachusetts General Hospital
Award amount:
£209,970
Location:
USA
Dr Zheng and his team are looking at how skin cancer cells alter the way they obtain and utilise energy from the sugar glucose when they become resistant to widely used skin cancer drugs.
Meet the scientist
Dr Zheng is Associate Professor of Dermatology at Harvard Medical School in Boston. His expertise in how cancer cells change to adapt to their increased thirst for energy has led to clinical trials investigating new treatments for skin cancer.
The science
Melanoma is the most deadly type of skin cancer, killing over 2,200 people each year in the UK and over 9,000 in the US. It is estimated that around 90% of melanoma cases can be prevented because the primary cause is over exposure to UV rays from the sun. Melanoma becomes deadly late on in the disease once it has spread to vital organs, so stopping this from happening is key to preventing melanoma related deaths.
Around 60% of all melanomas carry a genetic mutation to a gene called “B-Raf” and drugs that target this mutation show a lot of success in the clinic. However, many patients go on to develop resistance to this class of drugs known as BRAF inhibitors. Dr Bin Zheng is working out how this resistance occurs to find ways to overcome it.
The main cause of skin cancer is over exposure to UV rays from the sun - around 90% of skin cancer cases could be prevented through better protection from the sun.
Complete USA
Skin cancer
Researchers are hoping to kickstart new ways to prevent SCC or to diagnose SCC patients sooner to make it easier to treat the disease and improve survival rates.
Researcher: Dr Markus Schober
A new way to diagnose and prevent squamous cell carcinoma
Active United Kingdom
Bowel cancer
With your support, Professor Lesley Stark and her team in Edinburgh hope to find new ways to prevent cancer linked to ageing.
Researcher: Professor Lesley Stark
Journey to the centre of a cell: why does age matter in cancer?
Active Spain
General cancer research
Our project in Spain is exploring an innovative new 'dual-action' cancer cure
Researcher: Dr Edurne Rujas
Can ‘2 in 1’ therapy improve how we treat cancer?